# InflaRx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inflarx

- Industry: Biotechnology
- Headquarters: Jena, Germany
- Website: www.inflarx.com
- Total disclosed funding: $30M
- Latest round: Series D (Oct 13, 2017)
- Investors on record: 4

## About

InflaRx GmbH is a biopharmaceutical company focused on developing innovative treatments targeting inflammatory diseases by utilizing proprietary anti-C5a and C5a receptor inhibitors. Their approach aims to address critical health challenges globally.InflaRx GmbH, founded in 2007 and headquartered in Jena, Germany, specializes in developing treatments for inflammatory diseases. The company has undergone strategic pivots and has been recognized for its focus on innovative biopharmaceutical solutions. Renfeng Guo is the founder of the company, while Niels Riedemann serves as the CEO. InflaRx GmbH develops proprietary anti-C5a and C5a receptor (C5aR) inhibitors aimed at treating life-threatening and debilitating inflammatory diseases. Their primary product, GOHIBIC (vilobelimab), has received Emergency Use Authorization from the U.S. FDA for use in hospitalized adults with COVID-19, specifically for those requiring invasive mechanical ventilation or extracorporeal membrane oxygenation. This product targets the complement activation factor C5a, crucial in the inflammatory response. The company focuses on significant unmet medical needs in North America and Europe for severe inflammatory conditions.InflaRx generates revenue through the commercialization of its biopharmaceutical products, principally through sales of GOHIBIC to hospitals and healthcare systems under the FDA's Emergency Use Authorization. Revenue is derived from agreements with healthcare professionals and institutions, structured as direct sales to end-users, reflecting the urgency of need in treating severe inflammatory diseases. The pricing structures are determined based on market conditions and specific contracts with healthcare providers.InflaRx plans to enhance its product offerings and expand into new markets. The company is focused on developing additional products targeting severe inflammatory conditions. In May 2026, InflaRx GmbH raised USD 150 million in an IPO, selling 75 million shares at the Nasdaq all market, under the ticker symbol “IFRX.”

## Funding rounds

- Series D, Oct 13, 2017, $30M — RA Capital Management, Cormorant Asset Management
- Series B, Jul 17, 2014 — Bm-t
- Series A, Mar 17, 2009 — Bm-t, Affentranger Associates
- Seed, Mar 20, 2008 — Bm-t, Affentranger Associates

## Investors

- Bm-t (https://capitalatlas.ai/funds/bm-t) — Seed, Series A, Series B
- Affentranger Associates — Seed, Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series D
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series D